BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rx3 Pharmaceuticals, Inc. Creates New Clinical Advisory Board


9/26/2006 9:55:01 AM

SAN DIEGO, Sept. 26 /PRNewswire/ -- Rx3 Pharmaceuticals, Inc., an anti-infective drug discovery company, announced today that it has recently created a new Clinical Advisory Board (CAB) to complement its existing group of scientific advisers. Joining the new CAB are John S. Bradley, M.D., Henry Chambers, M.D., Robert Moellering, M.D., and Victor Nizet, M.D.

"These individuals are among the most highly regarded thought leaders in the field of antibacterial drug discovery and development," said Jeff Stein, Ph.D., Chairman of Rx3 Pharmaceuticals as well as Chairman of its current Scientific Advisory Board. "We expect that their deep knowledge and experience will contribute enormously to the Company's goal of developing new treatments for bacterial disease."

Dr. Bradley is Director of the Division of Infectious Diseases at Children's Hospital in San Diego. He is also a member of the FDA's anti-infective drugs advisory committee. Dr. Chambers is Chief of Infectious Diseases at San Francisco General Hospital and also a Professor at UCSF. He has over 100 publications in the areas of drug resistance and bacterial infections and is a reviewer for numerous medical publications. Dr. Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He has been actively involved in laboratory research related to antimicrobials for 30 years and he has over 350 publications in scientific journals. Dr. Nizet is Chief of the Division of Pharmacology & Drug Discovery at UCSD School of Medicine. His award winning research work has been recognized by the Dana-Farber Cancer Institute, the American Heart Association, and the American Lung Association.

More information on each of the four new CAB members can be found on the Company's web site.

About Rx3 Pharmaceuticals

Rx3 Pharmaceuticals is a drug discovery company applying its structure-based drug design technologies to its antimicrobial programs. These programs target novel proteins in validated pathways. For more information, visit www.rx3pharma.com.

Rx3 Pharmaceuticals, Inc.

CONTACT: John P. Schmid, Chief Financial Officer of Rx3 Pharmaceuticals,Inc., +1-858-452-0370, ext. 105, jschmid@rx3pharma.com; or Media, KarenKristofferson, Mentus, Life Science, +1-858-455-5500, ext. 275,karen@mentus.com, for Rx3 Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES